Prospective, observational study using rabeprazole in 455 patients with laryngopharyngeal reflux disease
- 11 January 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Archives Of Oto-Rhino-Laryngology
- Vol. 268 (6), 863-869
- https://doi.org/10.1007/s00405-010-1475-9
Abstract
The role of proton pump inhibitor in the treatment of laryngopharygneal reflux disease (LPRD) has been advocated, but there has been few reports dealing with large population based on time-related efficacy of rabeprazole. It was designed to assess the efficacy of rabeprazole and to evaluate which symptoms or findings varied significantly as medication sustained. Multiorgan, open-label cohort, prospective observational study was designed. We identified 1,142 patients with LPRD, and enrolled 455 patients, who participated fully in this survey and follow-up observation for 12 weeks. Reflux symptom index (RSI) and reflux finding score (RFS) were used to evaluate therapeutic efficacy. These parameters were evaluated at the 4th, 8th, and 12th weeks, respectively. Valid rate was used to explain improved proportion of patients after medication. The most common symptom was a globus sense in the throat. Posterior commissure hypertrophy was the most frequently encountered laryngoscopic finding. Female patients complained of heartburn and chest pain more than did male patients (P < 0.001), whereas male patients showed ventricular obliteration and erythematous changes more frequently than did female patients (P < 0.001). By RSI evaluation, scores gradually declined. Each item of the RSI improved at every visit (P < 0.001). Total RFS decreased progressively for 12 weeks and similar results were seen when every RFS item was individually examined. The proportion of patients who showed RSI and RFS falling by more than 50% after medication increased gradually as follow-up continued. This trend seemed to be significant (P < 0.001). Side effects of therapy were minimal. Despite the some constraints of an observational study, rabeprazole appeared to improve LPRD symptoms and signs. Prolonged medication at least 3 months may be beneficial to LPRD patients. Long-term medication effects require further evaluation.Keywords
This publication has 30 references indexed in Scilit:
- Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux diseaseAlimentary Pharmacology & Therapeutics, 2010
- Laryngopharyngeal reflux: More questions than answersCleveland Clinic Journal of Medicine, 2010
- Medical Therapy of Reflux LaryngitisJournal of Clinical Gastroenterology, 2008
- Hoarseness: Is It Really Laryngopharyngeal Reflux?The Laryngoscope, 2008
- Flexible Laryngoscopy-Guided Pharyngeal pH Monitoring in InfantsThe Laryngoscope, 2007
- Treatment of Chronic Posterior Laryngitis With EsomeprazoleThe Laryngoscope, 2006
- Changing Impact of Gastroesophageal Reflux in Medical and Otolaryngology PracticeThe Laryngoscope, 2005
- Review of rabeprazole in the treatment of gastro-oesophageal reflux diseaseExpert Opinion on Pharmacotherapy, 2004
- The Validity and Reliability of the Reflux Finding Score (RFS)The Laryngoscope, 2001
- Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplicationSurgery, 1998